A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 01 Sep 2024
At a glance
- Drugs Cetuximab (Primary) ; Pegenzileukin (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms Pegasus Head and Neck 204
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 09 Aug 2024 Planned End Date changed from 17 Feb 2025 to 19 Nov 2024.
- 08 Mar 2024 This trial has been Discontinued in Italy according to European Clinical Trials Database record.
- 13 Feb 2024 Planned End Date changed from 13 Aug 2024 to 17 Feb 2025.